Quidel Corp (NASDAQ: QDEL) reported Q3 EPS of $0.17, $0.21 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $50.9 million versus the consensus estimate of $50.26 million.

Third Quarter 2017 Financial Highlights

• Total revenue was $50.9 million as compared to $49.3 million in the third quarter of 2016.
• Total Immunoassay product revenue increased 19% from the third quarter of 2016.
• Total Molecular revenues increased 13% from the third quarter of 2016.
• Reported GAAP EPS of $(0.16) per share in the third quarter of 2017, as compared to $(0.02) per share in the third quarter of 2016 and reported non-GAAP EPS of $0.17 per diluted share in the third quarter of 2017, as compared to $0.10 per diluted share in the third quarter of 2016.

For earnings history and earnings-related data on Quidel Corp (QDEL) click here.